ArticleKidney international reports2022

In Reply to "Letter Regarding 'Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial'".

Masaaki Inaba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.